Home

כוס לדחוף למטה מפלגה camillo porta oncologo בת ערובה אחווה בכל פעם

Application of the Meet-URO score to metastatic renal cell carcinoma  patients treated with second- and third-line cabozantinib
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib

Loop | Camillo Porta
Loop | Camillo Porta

JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion)  Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome  Intratumoral Heterogeneity: The Meet-Uro 18 Study | HTML
JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study | HTML

Carcinoma renale a ESMO 2021, uno sguardo d'insieme - OncoInfo
Carcinoma renale a ESMO 2021, uno sguardo d'insieme - OncoInfo

Sorafenib as first- or second-line therapy in patients with metastatic  renal cell carcinoma in a community setting | Future Oncology
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology

Sorafenib as first- or second-line therapy in patients with metastatic  renal cell carcinoma in a community setting | Future Oncology
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology

SCIENTIFIC REPORT 2010 - 2011 - IOV
SCIENTIFIC REPORT 2010 - 2011 - IOV

Natural History of Malignant Bone Disease in Renal Cancer: Final Results of  an Italian Bone Metastasis Survey | PLOS ONE
Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey | PLOS ONE

Safety and efficacy of nivolumab for metastatic renal cell carcinoma:  real‐world results from an expanded access programme - De Giorgi - 2019 -  BJU International - Wiley Online Library
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme - De Giorgi - 2019 - BJU International - Wiley Online Library

Tumore del rene, quali sono le terapie più attuali - YouTube
Tumore del rene, quali sono le terapie più attuali - YouTube

Gaetano PEZZICOLI | Medical Doctor | Doctor of Medicine | Università degli  Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di  Scienze Biomediche ed Oncologia Umana (DIMO)
Gaetano PEZZICOLI | Medical Doctor | Doctor of Medicine | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO)

Loop | Camillo Porta
Loop | Camillo Porta

Docetaxel and prednisone with or without enzalutamide as first-line  treatment in patients with metastatic castration-resistant prostate cancer:  CHEIRON, a randomised phase II trial - ScienceDirect
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial - ScienceDirect

Adult Urology | Journal of Urology
Adult Urology | Journal of Urology

Daniel CASTELLANO | Hospital Universitario 12 de Octubre, Madrid |  12OCTUBRE | Medical Oncology Department
Daniel CASTELLANO | Hospital Universitario 12 de Octubre, Madrid | 12OCTUBRE | Medical Oncology Department

Nicola SILVESTRIS | Full professor | Professor | Università degli Studi di  Messina, Messina | UNIME - Page 4
Nicola SILVESTRIS | Full professor | Professor | Università degli Studi di Messina, Messina | UNIME - Page 4

Intervista Prof. Camillo Porta - YouTube
Intervista Prof. Camillo Porta - YouTube

Medical Oncology - ISPA
Medical Oncology - ISPA

Policlinico, Camillo Porta è il nuovo responsabile dell'UOC di Oncologia
Policlinico, Camillo Porta è il nuovo responsabile dell'UOC di Oncologia

Loop | Camillo Porta
Loop | Camillo Porta

Tweets with replies by Melissa Bersanelli (@Bersa_Dr_Mel) / Twitter
Tweets with replies by Melissa Bersanelli (@Bersa_Dr_Mel) / Twitter

Melissa Bersanelli (@Bersa_Dr_Mel) / Twitter
Melissa Bersanelli (@Bersa_Dr_Mel) / Twitter

thumbnail
thumbnail

Giampietro GASPARINI | Managing Director | Oncology
Giampietro GASPARINI | Managing Director | Oncology

Untitled
Untitled

Alessandra Bearz's research works | CRO Centro di Riferimento Oncologico di  Aviano, Aviano (CRO) and other places
Alessandra Bearz's research works | CRO Centro di Riferimento Oncologico di Aviano, Aviano (CRO) and other places

Sebastiano BUTI | Medical Doctor | MD, PhD | University Hospital of Parma,  Parma | AOUP | Reparto di Oncologia medica - Page 8
Sebastiano BUTI | Medical Doctor | MD, PhD | University Hospital of Parma, Parma | AOUP | Reparto di Oncologia medica - Page 8